EMA agrees to recall of Vimpat

The European Medicines Agency has agreed to a recall of Vimpat (lacosamide), a medicine used to treat epilepsy because of a quality defect in some batches. No adverse reactions have been reported. The developer, UCB SA, proposed the recall.